Abstract: A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials.
Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
Type:
Grant
Filed:
July 11, 2008
Date of Patent:
October 29, 2013
Assignee:
Allergan, Inc.
Inventors:
Robert T. Lyons, James N. Chang, John T. Trogden, Scott M. Whitcup
Abstract: Disclosed herein are anti-microbial wash compositions and methods for using such compositions in controlling microbe growth on a non-meat food product (e.g., fruits, vegetables, grains, eggs, etc.) by applying or contacting the anti-microbial wash composition with a surface of the food product to kill microbes (e.g., bacteria) on a surface of the food product. The anti-microbial wash compositions include a ceragenin compound dispersed in a fluid carrier. The ceragenin compound includes a sterol backbone and a number of cationic groups attached to the sterol backbone. The cationic groups may be attached to the sterol backbone by a hydrolysable linkage so that the ceragenin compound has a relatively short half life (e.g., less than about 40 days), and the wash composition may be applied prior to shipping and washed off after shipping to minimize any ceragenin compound residue.
Abstract: A drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. A sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.
Abstract: Topically applicable compositions in the form of oil-in-water (O/W) emulsions contain a pro-penetrating system including at least one glycol and at least one additional pro-penetrating agent, a suitable emulsifying system and at least one active agent of the family of steroidal anti-inflammatory agents, and are useful e.g., for the treatment of psoriasis.
Abstract: Topically applicable compositions in the form of oil-in-water emulsions contain a pro-penetrating system including at least one glycol and at least one additional pro-penetrating agent, a suitable gelling agent and at least one active agent of the family of steroidal anti-inflammatory agents and are useful, e.g., for the treatment of psoriasis.
Abstract: A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
February 19, 2003
Date of Patent:
September 24, 2013
Assignee:
Resolution Chemicals Limited
Inventors:
Parveen Bhatarah, Kenneth Alan Greenwood
Abstract: A composite that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 ?m, 50 nm to 10 ?m, 100 nm to 5 ?m, or 1 ?m to 10 ?m. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.
Abstract: Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell. Also provided are compounds useful for the treatment of Alexander disease in subjects at risk of or diagnosed with Alexander disease and methods for the identification of such compounds.
Type:
Application
Filed:
February 4, 2013
Publication date:
August 29, 2013
Inventors:
Albee Messing, Woosung Cho, Jon Scott Thorson, Randal D. Goff
Abstract: Prostate cancer (PC) is an entity that encompasses different types of tumors, including adenocarcinomas and non-adenocarcinomas. Adenocarcinomas and non-adenocarcinomas respond to, and therefore should be treated, with different treatments. Even within the adenocarcinomas, the lethality of tumors is highly variable, from low risk/indolent/non-life threatening to high risk/lethal. The inability to accurately predict the behavior of a particular cancer makes treatment decisions difficult and highly inexact. Elevated expression of prostate specific membrane antigen (PSMA) expression is a molecular hallmark of lethal prostate adenocarcinoma. Assessment of PSMA expression levels to predict the behavior of a particular cancer will be useful in the diagnosis and treatment of PC.
Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for later addition of cargo moieties are also contemplated.
Type:
Application
Filed:
April 1, 2013
Publication date:
August 29, 2013
Inventors:
Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.
Abstract: The present invention relates to methods, compositions, and diagnostic tests for diagnosing and treating lupus and other related diseases or disease subsets. In particular, the method, compositions, and diagnostic tests relate to a combination of one or more genes, where the expression of these genes indicates a predisposition to develop, or a diagnosis of, lupus and other related diseases or disease subsets.
Type:
Application
Filed:
August 12, 2011
Publication date:
August 22, 2013
Applicant:
Beth Israel Deaconess Medical Center Inc
Abstract: A method for treating a patient/subject having neuronal injury, pain, neurotrauma and/or traumatic brain injury, such as diffuse axonal injury, which includes intrathecally and/or intraventricularly administering to the subject a therapeutically effective amount of a non-steroidal anti-inflammatory drug and/or a naturally occurring omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.
Abstract: The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease.
Type:
Application
Filed:
June 10, 2011
Publication date:
August 15, 2013
Applicant:
The Regents of the University of California
Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
Type:
Application
Filed:
August 5, 2011
Publication date:
August 15, 2013
Applicant:
BETH ISRAEL DEACONESS MEDICAL CENTER, INC
Abstract: This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.
Abstract: The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.
Type:
Application
Filed:
May 9, 2011
Publication date:
August 8, 2013
Inventors:
Marie-Edith Rafestin-Oblin, Mouad Alami, Hugues Loosfelt, Abdallah Hamze, Ali Junaid Khan, Abdellatif Tikad, Marc Lombes, Jean-Daniel Brion
Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Abstract: The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.
Type:
Application
Filed:
February 2, 2013
Publication date:
August 8, 2013
Applicant:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventor:
Rutgers, The State University of New Jersey
Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.
Type:
Grant
Filed:
October 30, 2009
Date of Patent:
August 6, 2013
Assignee:
American Infertility of New York
Inventors:
Norbert Gleicher, David H. Barad, Dwyn V. Harben
Abstract: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.
Type:
Grant
Filed:
October 7, 2009
Date of Patent:
August 6, 2013
Assignee:
American Infertility of New York
Inventors:
Norbert Gleicher, David H. Barad, Dwyn V. Harben
Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.
Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.
Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a diaper having an inner layer having an absorbent core having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, boron, and chlorine; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate; and an outer layer.
Abstract: A Gantrez hydrogel comprising sodium, calcium, zinc, strontium, and ferric cations, and a polyvinylpyrrolidone based tack agent is disclosed. A method for preparation of the Gantrez hydrogel is also disclosed.
Abstract: A paraffin wax embedded drug delivery system is a method for combining topical medications with paraffin wax for enhanced delivery and absorption of the topical medication at a treatment area on a human body. A quantity of paraffin wax and a topical medication are provided, and mixture measurements are specified for a desired concentration and a desired ratio of ingredients for the mixture. To combine the topical medication and the paraffin wax, the quantity of paraffin wax is heated, the topical medication is added to the liquid paraffin wax, the mixture is agitated to ensure even combination, and the mixture is cooled. To apply the mixture, the mixture is heated back to its liquid state and applied to a treatment area using a wax bath, a brush, a roller, or another method.
Abstract: An implantable drug-doped component, e.g., a cochlear implant, includes host material, a host-embedded drug and a sacrificial material integrated with the host. Upon exposure of the sacrificial material to a solvent, e.g., perilymph fluid, voids in the host are created which facilitate release of the drug. The host can be, e.g., polysiloxane or silicone rubber. The sacrificial material, e.g., can be a glucose monomer, sugar, cyclodextrin, a salt, a bioresorbable material, hyaluronic acid, polyurethane, polyester, polyamide, polyvinyl alcohol, polyacrylic acid, etc. Alternatively, the sacrificial material can be the host, and can facilitate release of the drug through changing a property of the sacrificial material, e.g., by exposing the component to an ethanol wash. For a cochlear implant, e.g., the drug doped material can be applied to a non-stimulating surface of the electrode array.
Type:
Application
Filed:
January 20, 2012
Publication date:
July 25, 2013
Inventors:
Jane Rapsey, Martin Svehla, Peter Schuller, Christopher Robert Miller
Abstract: The object of the invention is the use as a drug of a compound fitting formula I wherein X represents an oxygen atom or a ?N—OH group and R represents a group selected from or one of its esters and/or of its addition salts with pharmaceutically acceptable acids, particularly as a cytoprotective drug, preferentially a cardioprotective and/or neuroprotective drug, the compounds of formula I wherein R is R2, R3, R4, R5 or R6 as novel compounds as well as their preparation method and use.
Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.
Type:
Grant
Filed:
May 17, 2010
Date of Patent:
July 9, 2013
Assignee:
Telomerase Activation Sciences, Inc.
Inventors:
Calvin B. Harley, Soo-Peang Khor, Mahesh Ramaseshan, Premchandran Ramiya, Zhu Zhen Pirot, Steven Fauce, Tong Lin
Abstract: Skin care compositions comprising certain substituted diamines, which are particularly beneficial for skin lightening and achieving evenness of color, especially for face and underarm skin.
Type:
Grant
Filed:
July 29, 2010
Date of Patent:
July 2, 2013
Assignee:
Conopco, Inc.
Inventors:
Jose Guillermo Rosa, Bijan Harichian, Diana Jean Drennan, John Steven Bajor, Carol Annette Bosko
Abstract: Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.
Abstract: Chronic obstructive pulmonary disease (COPD), characterized by chronic airflow limitation, is a serious and growing public health concern. The major environmental risk factor for COPD is cigarette smoking, but the biological mechanisms underlying COPD are not well understood. Herein, proton nuclear magnetic resonance (1H-NMR) spectroscopy is used in methods to identify metabolites and biomarkers associated with lung function in COPD.
Type:
Application
Filed:
July 3, 2012
Publication date:
June 13, 2013
Inventors:
Joseph Louie MCCLAY, Barbara K. ZEDLER, Edward Lenn MURRELLE, Edwin J.C.G. VAN DEN OORD, Thomas O'CONNELL, Daniel ADKINS
Abstract: A PEG based hydrogel and a procedure for its topical application to the surface of the pia mater of the spinal cord that can be used for intrathecal delivery of diverse drug and biomolecular therapies for the treatment of traumatic central nervous system injuries and disorders including spinal cord injury (SCI), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are provided. This “painting of the pia” with biofunctionalized hydrogel material may be used as a prelude strategy in the therapeutic management of these CNS disorders. The strategy may be designed to create a microenvironment within the damaged regions of the spinal cord that is more conducive to the successful application of subsequent regeneration based treatments such as cell replacement therapies or endogenous regeneration and plasticity stimulation via application of growth factors or gene therapy.
Abstract: An oil-in-water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, comprising: a first part including at least one occlusive agent and one or more lipophilic surfactants dispersed throughout a second part including water and at least one hydrophilic surfactant, and a non-surfactant amphiphilic type compound, pharmaceutically active ingredient, and water. It has been found that if a non-surfactant amphiphilic type compound is added together with the second part as would conventionally be the case, a microemulsion or sub-micron emulsion is not formed, by adding the so called third part, phase assembly occurs at a lower temperature than would be expected and moreover, this phase appears to assist in maintaining the microemulsion or sub-micron emulsion characteristics of the formulation during storage at normal temperatures.
Type:
Grant
Filed:
August 31, 2005
Date of Patent:
June 11, 2013
Assignee:
Stiefel Research Australia Pty Ltd
Inventors:
Maria Graziella Larm, Ronald Harding, Michael Johnston, Albert Zorko Abram, Prema Vijayakumar, Phoebe Sun
Abstract: Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.
Abstract: The present invention is directed to cellulosic gel compositions having improved viscosity stability through the exclusion of particular antioxidants and/or the exclusion of chemical entities that tend to produce free radicals. Preferably, the composition is an ophthalmic cellulosic gel composition that is suitable as a multi-dose composition.
Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
Type:
Grant
Filed:
June 8, 2012
Date of Patent:
May 28, 2013
Assignee:
Teva Womans's Health, Inc.
Inventors:
Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.
Type:
Grant
Filed:
June 25, 2009
Date of Patent:
May 28, 2013
Assignee:
Stiefel Research Australia Pty Ltd
Inventors:
Maria Graziella Larm, Ronald Harding, Michael Johnston, Albert Zorko Abram, Prema Vijayakumar, Phoebe Sun
Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.
Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 50 weight percent of a corticosteroid; and about 50 to about 99 weight percent biocompatible polymer.
Abstract: The disclosure relates to the development of methods for detecting or predicting graft-versus-host disease (GVHD) and for detecting or predicting response to treatment for GVHD. More particularly, the disclosure provides new biomarkers and combinations of biomarkers for detecting or predicting gastrointestinal GI GVHD and for predicting and analyzing response to treatment for acute GVHD.
Type:
Application
Filed:
October 3, 2012
Publication date:
May 9, 2013
Applicants:
FRED HUTCHINSON CANCER RESEARCH CENTER, The Regents Of The University Of Michigan
Inventors:
The Regents Of The University Of Michigan, Fred Hutchinson Cancer Research Center
Abstract: This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly(ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization from” approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling to” that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonal” chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.
Abstract: Provided herein are optimized methods for treating a degenerative muscle disease, which comprise determining the presence, absence or amount of a biomarker associated with the disease after a drug has been administered, and determining whether a subsequent dose of the drug should be maintained, increased or decreased based on the biomarker assessment. Increased levels of certain biomarkers are linked to muscle degenerative diseases (e.g., GM-CSF(CSF2), TNF-alpha or other pro-inflammatory cytokine acting through NF kappa B), and decreased levels of certain biomarkers are linked to the muscle degenerative diseases 9 e.g., particular microRNA (e.g., miRNA-1, miRNA-133, miRNA-206)). Such methods optimize therapeutic efficacy and minimize toxicity associated with a drug. Also provided herein are therapeutics for treating muscle disorders.
Type:
Application
Filed:
May 4, 2011
Publication date:
May 2, 2013
Applicant:
MEDIMMUNE, LLC
Inventors:
Yihong Yao, Robert William Georgantas, Wei Zhu, Katie Streicher, Koustubh Ranade
Abstract: This invention describes the use of sTNF-R as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the sTNF-R coated liposomes. The sTNF-R coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with sTNF-R and used to deliver the drug to the site of inflammation.
Abstract: The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) a method of inhibiting a SHIP1 protein in a cell; (iii) a method of selectively inhibiting a SHIP1 protein in a cell; (iv) a method for treating or preventing graft-versus-host disease (GVHD) in a recipient of an organ or tissue transplant; (v) a method of modulating SHIP activity in a cell expressing SHIP1 or SHIP2; (vi) a method of ex vivo or in vitro treatment of transplants; (vii) a method of inhibiting tumor growth and metastasis in a subject; (viii) a method of treating a hematologic malignancy in a subject; (ix) a method of inducing apoptosis of multiple myeloma cells; (x) a method of treating multiple myeloma in a subject; (xi) a method of inhibiting the proliferation of a human breast cancer cell; and (xii) a method of treating breast cancer in a subject.
Type:
Application
Filed:
April 11, 2011
Publication date:
April 25, 2013
Applicant:
The Research Foundation of the State University of New York
Abstract: The invention relates to therapeutic agents for use in the prevention or treatment of Alzheimer's disease. In particular the invention relates to use of inhibitors of cell cycle reentry and progression to the G1/S transition or inhibitors of progression of the cell cycle through the G1/S transition point in the prevention or treatment of Alzheimer's disease.
Abstract: The present invention relates to compounds of the following formula (I): or a pharmaceutically acceptable salt thereof, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, in which R represents a (C1-C10)alkyl group substituted with one or more, preferably one or two, groups chosen from COOH and NHR1, with R1 representing a hydrogen atom or a -Alk, —C(O)-Alk or —C(O)O-Alk group, Alk representing a (C1-C6)alkyl group, as well as a method for preparing them, and their use as a medicine, notably for treating an infection with a retrovirus such as HIV.
Type:
Application
Filed:
September 10, 2012
Publication date:
April 18, 2013
Applicants:
Universite Paris Descartes, Centre National de la Recherche Scientifique
Abstract: The present invention relates to methods for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one receptor selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.
Abstract: The present invention pertains to a filler comprising beads wherein said beads comprise a polyanionic biopolymer and divalent cations and wherein said polyanionic biopolymer is not alginate. Further, the present invention pertains to a process for manufacturing the claimed filler, and to an injection device comprising the filler.
Type:
Application
Filed:
April 7, 2011
Publication date:
April 11, 2013
Applicant:
MERZ PHARMA GmbH & CO., KGaA
Inventors:
Kevin Kiehm, Bernhard Hauptmeier, Peter Boderke